Peter W Atadja from 630 Mount Elam Rd, Fitchburg, MA 01420, age 65, Phone: 9783949928

Resumes

Executive Director And Head, Drug Discovery

view source

Location:

P/O Box 2857, Acton, MA

Industry:

Pharmaceuticals

Work:

Novartis Institutes For Biomedical Research (Nibr)
Executive Director and Head, Drug Discovery
Novartis Sep 1997 - Sep 2009
Group Leader
Novartis Sep 1997 - Sep 2009
Director and Head, Drug Discovery

Education:

University of Calgary 1991 - 1995
The Hebrew University of Jerusalem 1988 - 1991
Masters, Chemistry Kwame Nkrumah' University of Science and Technology, Kumasi
Kpando Secondary School

Skills:

Pharmacology
Ctr

Us Patents

Epothilone Resistant Cell Lines
view source
US Patent:

20040038324, Feb 26, 2004
Filed:

May 19, 2003
Appl. No.:

10/432072
Inventors:

Peter Atadja - Parsippany NJ, US
Markus Wartmann - Riehen, CH
Yan Yan-Neale - Edison NJ, US
Dalia Cohen - Livingston NJ, US
International Classification:

G01N033/574
C12N005/08
US Classification:

435/007230, 435/366000
Abstract:

Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothiolone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invetion also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.

Combination Of Histone Deacetylase Inhibitors With Chemotherapeutic Agents
view source
US Patent:

20070123580, May 31, 2007
Filed:

May 19, 2004
Appl. No.:

10/557162
Inventors:

Peter Atadja - Acton MA, US
Stacy Remiszewski - Washington Township NJ, US
Nancy Trogani - Boonton NJ, US
International Classification:

A61K 31/405
A61K 31/19
US Classification:

514419000, 514575000
Abstract:

The invention relates to a combination which comprises (a) one or more chemotherapeutic agents and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases including pre-malignant lesions (e.g. colon polyps) and malignancies, both solid and undifferentiated or other proliferative diseases in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of preventing or treating proliferative diseases including pre-malignant lesions (e.g. colon polyps) and malignancies, both solid and undifferentiated or other proliferative diseases, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.

Epothilone Resistant Cell Lines
view source
US Patent:

20070134744, Jun 14, 2007
Filed:

Jan 5, 2007
Appl. No.:

11/650375
Inventors:

Peter Atadja - Parsippany NJ, US
Markus Wartmann - Riehen, CH
Yan Yan-Neale - Edison NJ, US
Dalia Cohen - Livingston NJ, US
International Classification:

G01N 33/574
C12N 5/08
A61K 31/427
US Classification:

435007230, 435366000, 514365000
Abstract:

Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothilone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invention also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.

Combination Of A Histone Deacetylase Inhibitor With A Death Receptor Ligand
view source
US Patent:

20070258972, Nov 8, 2007
Filed:

Sep 17, 2004
Appl. No.:

10/571734
Inventors:

Peter Atadja - Acton MA, US
Kapil Bhalla - Tampa FL, US
International Classification:

A61K 45/06
A61K 38/00
A61P 35/02
C07C 233/00
A61K 39/395
US Classification:

424130100, 514002000, 514617000, 564161000
Abstract:

The invention relates to a method of preventing or treating proliferative diseases such as cancer in a mammal, particularly a human, with a combination of pharmaceutical agents which comprises: (a) an HDAI; and (b) a death receptor ligand. The invention further relates to pharmaceutical compositions comprising: (a) an HDAI; (b) death receptor ligand; and (c) a pharmaceutically acceptable carrier. The present invention further relates to a commercial package or product comprising: (a) a pharmaceutical formulation of an HDAI; and (b) a pharmaceutical formulation of death receptor ligand for simultaneous, concurrent, separate or sequential use.

Combination Of Organic Compounds
view source
US Patent:

20080200489, Aug 21, 2008
Filed:

Aug 10, 2006
Appl. No.:

12/063172
Inventors:

Peter Wisdom Atadja - Acton MA, US
Kapil N. Bhalla - Tampa FL, US
Paul W. Manley - Arleshiem, CH
International Classification:

A61K 31/506
A61P 35/02
US Classification:

514275
Abstract:

The invention provides a pharmaceutical combination comprising:

Use Of Hdac Inhibitors For The Treatment Of Myeloma
view source
US Patent:

20080221126, Sep 11, 2008
Filed:

Aug 1, 2006
Appl. No.:

11/996323
Inventors:

Peter W. Atadja - Acton MA, US
International Classification:

A61K 31/4965
A61K 31/4045
A61P 35/00
US Classification:

51425506, 514415
Abstract:

The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula I,wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma cells, preferably bortezomib, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.

Use Of Hdac Inhibitors For The Treatment Of Lymphomas
view source
US Patent:

20090281159, Nov 12, 2009
Filed:

Jun 26, 2007
Appl. No.:

12/305245
Inventors:

Peter Wisdom Atadja - Acton MA, US
Wenlin Shao - Dedham MA, US
Assignee:

NOVARTIS AG - Basel
International Classification:

A61K 31/405
A61K 31/34
A61K 31/165
US Classification:

514415, 514469, 514619
Abstract:

The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I):wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of lymphoproliferative diseases, in particular, cutaneous T-cell lymphomas.

Combination Of An Hdac Inhibitor And An Antimetabolite
view source
US Patent:

20100069318, Mar 18, 2010
Filed:

Nov 30, 2007
Appl. No.:

12/516656
Inventors:

Peter Wisdom Atadja - Acton MA, US
Assignee:

NOVARTIS AG - Basel
International Classification:

A61K 31/70
A61K 31/165
US Classification:

514 43, 514620
Abstract:

The invention relates to a combination which comprises:

Peter W Atadja

Peter Atadja Phones & Addresses

Work

Education

Skills

Industries

Resumes

Executive Director And Head, Drug Discovery

Us Patents

Epothilone Resistant Cell Lines

Combination Of Histone Deacetylase Inhibitors With Chemotherapeutic Agents

Epothilone Resistant Cell Lines

Combination Of A Histone Deacetylase Inhibitor With A Death Receptor Ligand

Combination Of Organic Compounds

Use Of Hdac Inhibitors For The Treatment Of Myeloma

Use Of Hdac Inhibitors For The Treatment Of Lymphomas

Combination Of An Hdac Inhibitor And An Antimetabolite